Previous studies from our group have shown that administration of the KCa2.3/KCa3.1 channel activator SKA-31 (Sankaranarayanan et al., 2009) can restore endothelial function in arteries from aged (Mathew John et al., 2020) and type 2 diabetic rats (Mishra et al., 2021; Mishra et al., 2024) that exhibit endothelial dysfunction. Here, KCNN3 is linked to type 2 diabetes mellitus.